Skip to content

Driving breakthroughs in cancer care:

Discover Flatiron Health’s research at ASCO 2023

At ASCO 2023, we are excited to showcase our latest advancements in oncology research and our commitment to helping patients with cancer. 

  • Our use of real-world data allows us to enhance the representativeness of cancer treatment trials and generate insights into diverse patient populations, thus unlocking the opportunities for improving health equity.

  • Our clinical research technology ensures more effective, efficient, and less burdensome clinical trials through trial design decision-making, optimized patient enrollment, clinical data acquisition and automated data delivery. 

  • Finally, our advanced AI methodologies, such as machine learning and natural language processing, allow us to learn more from patients, faster, so we can accelerate oncology drug development and answer timely research questions as the standard of care changes.  

Aligned with ASCO 2023’s theme of “Partnering with patients: The cornerstone of cancer care and research,” our research aims to revolutionize how we understand and address diverse patient experiences, bringing us closer to better, more equitable cancer care. As we explore how real-world evidence and technology can improve cancer treatments and make them more accessible, we remain committed to using data for good. We are excited to share our insights with the scientific community and continue to work towards reimagining the infrastructure of cancer care. 

Our research

Oral abstract session

Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types

Gandara D, Agarwal N, Gupta S, Klempner S, Andrews M, Mahipal A, Subbiah V, Eskander R, Carbone D, Snider J, Bouzit L, Cho-Phan C, Price M, Li G, Quintanilha J, Huang R, Ross J, Fabrizio D, Oxnard G, Graf R

To evaluate the clinical validity of the FDA-approved TMB measurement test, this study analyzed a large real-world dataset of over 8,000 patients with 24 different cancer types who received single-agent immune checkpoint inhibitors and had validated rwOS endpoint data.

Oral abstract session

Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting

Vidal G, Jain N, Fisher A, Sheinson D, Lofgren K, Ma E, Yu E, Comment L, Miksad R, Daniel D

The findings from this study can help researchers and policy-makers identify areas where policy interventions can be implemented to promote greater equity in access to NGS testing.


Mediators of racial/ethnic inequities in clinical trial participation among US patients with cancer, 2011-2022

Guadamuz JS, Calip GS, Ryals CA, Altomare I, Wang X

This research uncovers social determinants of health factors that play a role in the disparate participation of patients from different racial/ethnic backgrounds in clinical trials involving 22 types of solid and blood cancers.


Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets

McKelvey B, Garrett-Mayer E, Belli A, Brown T, Dow J, Espirito J, Kluetz P, Ma Xinran, McCracken A, Mishra-Kalyani P, Natanzon Y, Potter D, Rivera D, Stires H, Stewart M, Allen J

Developing a reliable clinician-assessed real-world response endpoint can help regulators characterize drug effectiveness using RWD sources to inform regulatory decision-making.


Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns

Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K

Continuing treatment beyond the point of benefit can result in adverse outcomes. By addressing the knowledge gap of whether oncology practice-level “aggressive” use of SACT at the EOL is associated with overall survival benefit among all patients with advanced solid tumors, we can help to develop more effective interventions to improve the quality of care.


Evaluating generalizability of practice-changing randomized clinical trials in non-small cell lung cancer using machine learning-based in-silico trials

Orcutt X, Mamtani R, Sondhi A, Cohen A, Parikh R

The objective of this study was to evaluate the generalizability of survival outcomes reported in five phase III trials that led to changes in clinical practice for patients with advanced non-small cell lung cancer in the first-line setting.


Metastatic patterns and outcomes by HER2 and hormone receptor status in patients with metastatic breast cancer

Yuan Q, Castellanos E, Fidyk E, Schwed K, Estevez M, Nemeth S, Linzmayer R, Cohen A

In this study, researchers aimed to understand the prognostic implications of HER2-low status by examining the distribution of metastases as well as real-world overall survival according to HER2 and hormone receptor status.


Technology-enabled clinical trials: Intentional capture of source data in the electronic-health record and direct transfer to trial database in a phase II multicenter trial

Royce T, Falk S, Xiao F, Boyd M, Bramwell L, Shelley A, Sutton L, Morgan R, Mader P, Taiclet T, Alve A

This study focuses on a pilot implementation of transferring structured EHR data to an electronic data capture (EDC) system in a Phase II multicenter clinical trial.


Trial eligibility criteria and diversity among patients with advanced non small cell lung cancer

Kaur M, Frahm F, Ascha M, Guadamuz JS, Gottesman A, Leybovich B, Sondhi A, Zhao Y, Meropol N, Royce T

The FDA has provided guidance supporting the use of real-world data in the development of diversity plans for clinical trials. These plans may involve the implementation of more inclusive or broader eligibility criteria to enhance the participation of populations historically underrepresented in clinical trials. This study examined the impact of expanding eligibility criteria on the diversity of participants with advanced non-small lung cancer.


Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice

Richardson D, Quintanilha J, Grof R, Danziger N, Washington C, Dockery L, Snow T, Afghahi A, Frachioni A, Elvin J, Moore K

Using the Flatiron Health-Foundation Medicine Clinico-Genomic Database, this study aimed to compare the effectiveness of mPARPi in real-world practice based on two biomarkers: BRCA1/2 mutation and/or a novel biomarker called HRD signature.


Clinical pathways innovation: A lesson on the value of clinician based feedback and collaboration with Flatiron Health

Davella C, Bange E, Singh A, Dougherty D, Gabriel P, Maniango R, Miao J, Harvey C, Ricottone M, Shulman L

Examining the impact clinician-based feedback had on improving the usability of the Flatiron Assist tool may provide valuable insights into how we can overcome this adoption challenge, ultimately leading to improved care and outcomes for cancer patients.

Online publication

Representativeness in cancer treatment trials in community and academic settings

Altomare I, Wang X, Falk S, Kaur M, Guadamuz JS, Xiao F, Meropol N, Zhao Y

The representativeness of clinical trial participants with cancer is a crucial aspect in the generalizability of research findings to the broader patient population. However, the impact of practice setting on the representativeness of trial participants remains unknown.

Get started with Flatiron